Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pafolacianine for Localization of Pediatric Extracranial Solid Tumors
NCT06915727Phase 3Recruiting
- Sponsor
- Mayo Clinic
- Start
- Apr 2025
- Primary completion
- May 2027
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pafolacianine in solid tumor, sponsored by Mayo Clinic. Primary endpoint: Accuracy of pafolacianine injection used with NIR fluorescent imaging for detecting lesions at 30 days. Started Apr 2025; status: recruiting.
02
Drugs
pafolacianine
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06915727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06915727.